- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05131828
CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy
The greatest unmet need for people with multiple sclerosis is an effective therapy for the progressive phase. Current treatments suppress the damage caused by the immune system but there is only a limited window in which these can work. Consequently, much of the research community is turning its attention to the process of repair, called remyelination, in which the lining of nerve cells is reformed. This protects nerves from dying and therefore can delay, prevent, or even reverse, disability progression.
It has previously been shown that stem cells are already present in the brain that can carry out this process. Clemastine, an anti-histamine drug, can instruct them to become active and has already shown a beneficial effect in a phase 2 trial. Now, more recent experiments have shown that changes take place within these stem cells as they age, which prevents them responding to drugs like clemastine, but that this can be reversed by treatment with metformin, a commonly used anti-diabetes drug.
Our goal is to establish whether the combination of metformin and clemastine can promote remyelination in people with MS. We will focus on people with relapsing MS as they will have a greater proportion of nerves healthy enough to allow remyelination to take place, which will maximise the chance of detecting an effect with a smaller sample size.
Participants will also continue treatment with a current disease-modifying MS treatment, to reduce the chance of developing new areas of damage, allowing the trial to focus on the repair process. The treatment duration will be 24 weeks, but given the established safety of the proposed medications, we are able to limit the number of visits to the trial centre to ensure participation is not overly burdensome.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: CCMR Trials Team
- Phone Number: 01223 216187
- Email: cuh.ccmr-trials@nhs.net
Study Locations
-
-
-
Cambridge, United Kingdom
- Recruiting
- Addenbrooke's Hospital
-
Contact:
- CCMR Trials Team
- Email: cuh.ccmr-trials@nhs.net
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participant is willing and able to give written informed consent for participation in the trial;
- Male or female, aged between 25 and 50 years (inclusive) at time of signing informed consent form (ICF);
- Relapsing-remitting multiple sclerosis as per the McDonald 2017 criteria (Thompson et al., 2018), including an MRI brain satisfying the McDonald 2017 criteria;
- VEP P100 latency in at least one eye of ≥118 ms;
- Kurtzke EDSS 0.0-6.0;
- At the time of screening being treated with a stable dose for at least 6 months of a category 1 multiple sclerosis DMT or for at least 2 years with a category 2 DMT;
- Able (in the Investigator's opinion) and willing to comply with all trial requirements.
Exclusion Criteria:
- Female participants who are pregnant, lactating or planning pregnancy during the course of the trial;
- Female participants of child-bearing potential whom are unwilling or unable to use one highly effective method of contraception during the trial (as outlined in section 11.11). For the purpose of this document, a woman is considered of childbearing potential, i.e. fertile, following menarche and until post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause;
- Male participants who are unwilling or unable to use contraception during and for 3 months after the trial;
- Participants whom have received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 4 weeks before the screening assessment or is currently enrolled in an interventional investigational trial;
- Retinal nerve layer thickness on spectral-domain optical coherence tomography (OCT) <70 μm in the qualifying eye;
- A clinical episode of optic neuritis in the qualifying eye within the 2 years preceding screening;
- Any unlicensed treatment of multiple sclerosis;
- Any concomitant use of oxybutynin, monoamine oxidase inhibitors (MAOIs), hypnotics or high-dose opiates at screening;
- Significant renal impairment (eGFR <60 mL/min/1.73 m2);
- Screening liver function (alanine aminotransferase, ALT) value greater than 3 times the upper limit of normal;
- Known hypersensitivity to metformin or clemastine (or other arylalkylamine antihistamines) or any of the excipients of these products;
- People taking medication for Diabetes Mellitus at screening;
- People with a diagnosis of epilepsy;
- People with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption;
- Concurrent use of 4-aminopyridine or fampridine;
- Known contraindication(s) to MRI scanning procedures;
- History of prostatic hypertrophy;
- History of major ophthalmologic disease or concomitant ophthalmologic disorders including glaucoma, macular degeneration, and severe myopia (>-7 Diopters);
- History of stenosing peptic ulcer or pyloroduodenal ulceration;
- History of significant cardiac conduction block or decompensated heart failure;
- History of acute porphyria;
- People with a history of alcohol or other recreational drug misuse within the 6 months preceding screening;
- People unable to avoid alcohol drinks for the course of the trial;
- Vitamin B12 deficiency as defined as B12 levels of < 150 pg/ml measured at screening;
- Any other significant disease, disability or investigation result which, in the opinion of the Investigator, may either put the participant at risk, or may influence the result of the trial, or the participant's ability to participate in the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Research arm: metformin and clemastine
|
Metformin hydrochloride 500 mg prolonged release (SR) tablet for oral administration. Clemastine hydrogen fumarate 1.34 mg tablet for oral administration. |
Placebo Comparator: Control arm: placebos for both metformin + clemastine
|
Placebo tablets to match both metformin and clemastine tablets.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
the change in the P100 latency of the full-field visual evoked potential (VEP) between baseline and week 26 for each affected eye of participants
Time Frame: Baseline to week 26
|
Baseline to week 26
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The change in MF-VEP latency, between baseline and week 26, for those eyes with delayed latency at baseline
Time Frame: Baseline to week 26
|
Baseline to week 26
|
The change in lesional MTR, between baseline and week 26, for the lesions stratified by location
Time Frame: Baseline to week 26
|
Baseline to week 26
|
Adverse events and withdrawals attributable to metformin and/or clemastine
Time Frame: Baseline to week 28
|
Baseline to week 28
|
The change in lesional MTR between baseline and week 26, for the lesions stratified by tissue-specific cohort baseline lesional MTR values
Time Frame: Baseline to week 26
|
Baseline to week 26
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The change, between baseline and week 26, in the N75 and N145 latencies of the full-field VEP
Time Frame: Baseline to week 26
|
Baseline to week 26
|
The change in full field VEP amplitude, between baseline and week 26, for those eyes with delayed latency at baseline
Time Frame: Baseline to week 26
|
Baseline to week 26
|
The change in MF-VEP amplitude, between baseline and week 26, for those eyes with delayed latency at baseline
Time Frame: Baseline to week 26
|
Baseline to week 26
|
The change in the number of letters read (and the corresponding LogMAR score) on the Sloan 100%, 2.5% and 1.25% acuity charts, between baseline and week 28
Time Frame: Baseline to week 28
|
Baseline to week 28
|
The change in colour vision between baseline and week 28
Time Frame: Baseline to week 28
|
Baseline to week 28
|
The change in visual fields between baseline and week 28
Time Frame: Baseline to week 28
|
Baseline to week 28
|
The change in saccadic latency parameters in the step, antisaccade and Wheeless tasks between screening and week 28
Time Frame: Screening to week 28
|
Screening to week 28
|
The change in retinal nerve fibre layer thickness between screening and week 28
Time Frame: Screening to week 28
|
Screening to week 28
|
The change in MRI T2 lesion load between baseline and week 26
Time Frame: Baseline to week 26
|
Baseline to week 26
|
The change in EDSS between screening and week 26
Time Frame: Screening to week 26
|
Screening to week 26
|
The change in MTR of lesional subcomponents and lesional voxels, stratified by location, between baseline and week 26
Time Frame: Baseline to week 26
|
Baseline to week 26
|
The change in lesional MTR between baseline and week 26, for different lesion types
Time Frame: Baseline to week 26
|
Baseline to week 26
|
The change between baseline and week 26 measured by different MRI biomarkers of remyelination
Time Frame: Baseline to week 26
|
Baseline to week 26
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Nick Cunniffe, Cambridge University Hospitals NHS Foundation Trust & University of Cambridge
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Multiple Sclerosis
- Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Dermatologic Agents
- Anti-Allergic Agents
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Antipruritics
- Metformin
- Clemastine
Other Study ID Numbers
- CCTU0269
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Metformin and clemastine in combination
-
Zagazig UniversityCompletedPCOS (Polycystic Ovary Syndrome) of Bilateral OvariesEgypt
-
Namyi GuUnknownDiabetes MellitusKorea, Republic of
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesUnited States, Puerto Rico
-
SanofiHanmi Pharmaceutical Company LimitedTerminatedType 2 Diabetes MellitusUnited States, China, Taiwan
-
Radboud University Medical CenterCompleted
-
Dalim BioTech Co., Ltd.CompletedDiabetes Mellitus, Type 2Korea, Republic of
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesUnited States
-
Novo Nordisk A/SCompleted
-
Amsterdam UMC, location VUmcRecruitingMultiple Sclerosis | Internuclear OphthalmoplegiaNetherlands
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesUnited States